Yeast model reveals alzheimer's drug candidate and its mechanism of action

A yeast cell-based drug screen has been used by researchers to identify a class of molecules that target the amyloid-beta (Abeta) peptide involved in Alzheimer's disease (AD). The U.S. National Institute on Aging estimates that 5.1 million Americans may have AD, the most common form of dementia, which progressively robs patients of their memories, thinking, and reasoning skills.